Literature DB >> 26349821

Augmented renal clearance implies a need for increased amoxicillin-clavulanic acid dosing in critically ill children.

Pieter A J G De Cock1, Joseph F Standing2, Charlotte I S Barker3, Annick de Jaeger4, Evelyn Dhont4, Mieke Carlier5, Alain G Verstraete6, Joris R Delanghe6, Hugo Robays7, Peter De Paepe8.   

Abstract

There is little data available to guide amoxicillin-clavulanic acid dosing in critically ill children. The primary objective of this study was to investigate the pharmacokinetics of both compounds in this pediatric subpopulation. Patients admitted to the pediatric intensive care unit (ICU) in whom intravenous amoxicillin-clavulanic acid was indicated (25 to 35 mg/kg of body weight every 6 h) were enrolled. Population pharmacokinetic analysis was conducted, and the clinical outcome was documented. A total of 325 and 151 blood samples were collected from 50 patients (median age, 2.58 years; age range, 1 month to 15 years) treated with amoxicillin and clavulanic acid, respectively. A three-compartment model for amoxicillin and a two-compartment model for clavulanic acid best described the data, in which allometric weight scaling and maturation functions were added a priori to scale for size and age. In addition, plasma cystatin C and concomitant treatment with vasopressors were identified to have a significant influence on amoxicillin clearance. The typical population values of clearance for amoxicillin and clavulanic acid were 17.97 liters/h/70 kg and 12.20 liters/h/70 kg, respectively. In 32% of the treated patients, amoxicillin-clavulanic acid therapy was stopped prematurely due to clinical failure, and the patient was switched to broader-spectrum antibiotic treatment. Monte Carlo simulations demonstrated that four-hourly dosing of 25 mg/kg was required to achieve the therapeutic target for both amoxicillin and clavulanic acid. For patients with augmented renal function, a 1-h infusion was preferable to bolus dosing. Current published dosing regimens result in subtherapeutic concentrations in the early period of sepsis due to augmented renal clearance, which risks clinical failure in critically ill children, and therefore need to be updated. (This study has been registered at Clinicaltrials.gov as an observational study [NCT02456974].).
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26349821      PMCID: PMC4604416          DOI: 10.1128/AAC.01368-15

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  35 in total

1.  Development of a pediatric multiple organ dysfunction score: use of two strategies.

Authors:  S Leteurtre; A Martinot; A Duhamel; F Gauvin; B Grandbastien; T V Nam; F Proulx; J Lacroix; F Leclerc
Journal:  Med Decis Making       Date:  1999 Oct-Dec       Impact factor: 2.583

2.  Ways to fit a PK model with some data below the quantification limit.

Authors:  S L Beal
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-10       Impact factor: 2.745

3.  Reference ranges for plasma cystatin C and creatinine measurements in premature infants, neonates, and older children.

Authors:  H Finney; D J Newman; H Thakkar; J M Fell; C P Price
Journal:  Arch Dis Child       Date:  2000-01       Impact factor: 3.791

4.  Cystatin C as a new covariate to predict renal elimination of drugs: application to carboplatin.

Authors:  Fabienne Thomas; Sophie Séronie-Vivien; Laurence Gladieff; Florence Dalenc; Valérie Durrand; Laurence Malard; Thierry Lafont; Muriel Poublanc; Roland Bugat; Etienne Chatelut
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

5.  A population pharmacokinetic model for cefuroxime using cystatin C as a marker of renal function.

Authors:  Anders Viberg; Anders Lannergård; Anders Larsson; Otto Cars; Mats O Karlsson; Marie Sandström
Journal:  Br J Clin Pharmacol       Date:  2006-09       Impact factor: 4.335

6.  Cystatin C vs creatinine as markers of renal function in patients on digoxin treatment.

Authors:  Pär Hallberg; Håkan Melhus; Lars-Olof Hansson; Anders Larsson
Journal:  Ups J Med Sci       Date:  2004       Impact factor: 2.384

Review 7.  Vasoactive drugs and the kidney.

Authors:  Raymond Wai Chuen Lee; David Di Giantomasso; Clive May; Rinaldo Bellomo
Journal:  Best Pract Res Clin Anaesthesiol       Date:  2004-03

Review 8.  Developmental pharmacology--drug disposition, action, and therapy in infants and children.

Authors:  Gregory L Kearns; Susan M Abdel-Rahman; Sarah W Alander; Douglas L Blowey; J Steven Leeder; Ralph E Kauffman
Journal:  N Engl J Med       Date:  2003-09-18       Impact factor: 91.245

9.  Cytochrome P450 mediated-drug metabolism is reduced in children with sepsis-induced multiple organ failure.

Authors:  Joseph A Carcillo; Lesley Doughty; Danny Kofos; Reginald F Frye; Sandra S Kaplan; Howell Sasser; Gilbert J Burckart
Journal:  Intensive Care Med       Date:  2003-04-16       Impact factor: 17.440

10.  Impact of tazobactam pharmacokinetics on the antimicrobial effect of piperacillin-tazobactam combinations.

Authors:  Q Liu; K Rand; H Derendorf
Journal:  Int J Antimicrob Agents       Date:  2004-05       Impact factor: 5.283

View more
  24 in total

1.  Incidence of contrast-induced acute kidney injury in a pediatric setting: a cohort study.

Authors:  Aymeric Cantais; Zeineb Hammouda; Olivier Mory; Hugues Patural; Jean-Louis Stephan; Lyudmyla Gulyaeva; Michael Darmon
Journal:  Pediatr Nephrol       Date:  2016-03-21       Impact factor: 3.714

Review 2.  Clinical Pharmacology Studies in Critically Ill Children.

Authors:  Nilay Thakkar; Sara Salerno; Christoph P Hornik; Daniel Gonzalez
Journal:  Pharm Res       Date:  2016-09-01       Impact factor: 4.200

3.  Population Pharmacokinetics and Pharmacodynamic Target Attainment of Meropenem in Critically Ill Young Children.

Authors:  Jeffrey J Cies; Wayne S Moore; Adela Enache; Arun Chopra
Journal:  J Pediatr Pharmacol Ther       Date:  2017 Jul-Aug

4.  Optimizing Aminoglycoside Dosing Regimens for Critically Ill Pediatric Patients with Augmented Renal Clearance: a Convergence of Parametric and Nonparametric Population Approaches.

Authors:  Sean N Avedissian; Roxane Rohani; John Bradley; Jennifer Le; Nathaniel J Rhodes
Journal:  Antimicrob Agents Chemother       Date:  2021-03-18       Impact factor: 5.191

5.  [Effect of augmented renal clearance on plasma concentration of vancomycin and treatment outcome in children with methicillin-resistant Staphylococcus aureus infection].

Authors:  Cui-Yao He; Yan-Ran Qin; Cheng-Jun Liu; Jie Ren; Ji-Shan Fan
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2019-09

6.  Augmented renal clearance: a common condition in critically ill children.

Authors:  Tatjana Van Der Heggen; Evelyn Dhont; Harlinde Peperstraete; Joris R Delanghe; Johan Vande Walle; Peter De Paepe; Pieter A De Cock
Journal:  Pediatr Nephrol       Date:  2019-02-18       Impact factor: 3.714

7.  Scaling beta-lactam antimicrobial pharmacokinetics from early life to old age.

Authors:  Dagan O Lonsdale; Emma H Baker; Karin Kipper; Charlotte Barker; Barbara Philips; Andrew Rhodes; Mike Sharland; Joseph F Standing
Journal:  Br J Clin Pharmacol       Date:  2018-11-26       Impact factor: 4.335

8.  Clinical Pharmacokinetics of Vancomycin in Critically Ill Children.

Authors:  Kannan Sridharan; Amal Al Daylami; Reema Ajjawi; Husain Al-Ajooz; Sindhan Veeramuthu
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2019-12       Impact factor: 2.441

9.  Augmented renal clearance in pediatric intensive care: are we undertreating our sickest patients?

Authors:  Evelyn Dhont; Tatjana Van Der Heggen; Annick De Jaeger; Johan Vande Walle; Peter De Paepe; Pieter A De Cock
Journal:  Pediatr Nephrol       Date:  2018-10-29       Impact factor: 3.714

10.  Piperacillin Population Pharmacokinetics and Dosing Regimen Optimization in Critically Ill Children with Normal and Augmented Renal Clearance.

Authors:  Agathe Béranger; Sihem Benaboud; Saïk Urien; Florence Moulin; Emmanuelle Bille; Fabrice Lesage; Yi Zheng; Mathieu Genuini; Inès Gana; Sylvain Renolleau; Déborah Hirt; Jean-Marc Tréluyer; Mehdi Oualha
Journal:  Clin Pharmacokinet       Date:  2019-02       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.